MedPath

MURIM: MUltidisciplinary Research on Implantation failure and Miscarriage

Recruiting
Conditions
infertility
Subfertility
10013356
Registration Number
NL-OMON56176
Lead Sponsor
Medisch Universitair Ziekenhuis Maastricht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
249
Inclusion Criteria

Repeated implantation failure
- Female aged 18-38 years old
- Repeated implantation failure (RIF) defined as:
- failure of implantation of three high quality embryo*s or after placement of
ten or more embryo*s in multiple transfers
- Primary or secondary infertility
- Written informed consent

Recurrent miscarriages
- Female aged 18-38 years old
- Repeated, unexplained miscarriages (RM) defined as 2 or more unexplained
miscarriages not caused by abnormal parental karyotype, maternal thrombophilia
and/or uterine abnormalities
- Written informed consent

Control
- Female aged 18-38 years old
- Uneventful previous pregnancy defined as no preterm delivery, pre-eclampsia
or fetal growth restriction and live birth OR presumed fertile defined as an
indication for PESA/TESE, female sterilisation, or PGD indication for genetic
analysis without subfertility treatment
- Written informed consent

Exclusion Criteria

Repeated implantation failure
- Clinically relevant intra-uterine pathology
- BMI > 35 kg/m2
- Untreated endocrine abnormalities
- PGD treatment

Recurrent miscarriages
- Current or recent (<3 months ago) pregnancy, breastfeeding or hormonal
contraceptive
- Current symptomatic genital infection
- BMI > 35 kg/m2

Control group
- Recurrent miscarriages or repeated implantation failure
- Current or recent (<3 months ago) pregnancy, breastfeeding or current
hormonal contraceptive use
- BMI > 35 kg/m2
- Severe endometriosis (3th -4th degree)

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameters are steroid profile in endometrial tissue and serum,<br /><br>activity of steroid enzymes, phenotype and function of Natural Killer cells,<br /><br>presence of HLA antibodies, determination of the vaginal microbiome and<br /><br>volatile organic compounds.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Not applicable</p><br>
© Copyright 2025. All Rights Reserved by MedPath